/Companies

Draupnir Bio

Copenhagen, DK · Founded 2017 · 19 employees on LinkedIn · 4 known investors

Find your way into Draupnir Bio

Sign up to find every way you can get introduced to Draupnir Bio

  • Your email: who you already know at Draupnir Bio, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Draupnir Bio team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Draupnir Bio develops targeted protein degradation therapies using sortilin-based lysosome targeting chimeras to clear extracellular and membrane-bound protein aggregates in proteinopathies. The company, a spin-out from Aarhus University and Max-Planck Society, builds proprietary platform technology to treat diseases with significant unmet medical need.

Founders & leadership

Draupnir Bio was founded in 2017 by Simon Glerup, Camilla Gustafsen, Peder Søndergaard Madsen, and Peter Seeberger.

SGSimon Glerup
Simon GlerupProfessorCo-founder at Teitur Trophics
CG
Camilla GustafsenProfessorProfessor at Draupnir
PS
Peder Søndergaard MadsenProfessor
PS
Peter SeebergerProfessor

Investors · 4

In the news

Frequently asked questions

What does Draupnir Bio do?
Draupnir Bio develops targeted protein degradation therapies using sortilin-based lysosome targeting chimeras to clear extracellular and membrane-bound protein aggregates in proteinopathies. The company, a spin-out from Aarhus University and Max-Planck Society, builds proprietary platform technology to treat diseases with significant unmet medical need.
Who founded Draupnir Bio?
Draupnir Bio was founded by Simon Glerup, Camilla Gustafsen, Peder Søndergaard Madsen, Peter Seeberger in 2017.
Who are Draupnir Bio's investors?
Draupnir Bio's investors include Inkef, Gilde Healthcare, MC Healthcare Ventures, Novo Holdings.
Where is Draupnir Bio headquartered?
Draupnir Bio is headquartered in Copenhagen, DK.